Doron Therapeutics, a Chapel Hill, NC-based clinical-stage biotech company focusing on degenerative musculoskeletal conditions, raised $11M in Series A funding.
The round was led by SPRIM Global Investments (SGI).
The company intends to use the funds to take MOTYS™ into Phase 3 clinical studies.
Led by CEO Doron is a is a clinical-stage biotechnology company advancing MOTYS™, an intra-articular biologic drug developed for the management of symptomatic knee osteoarthritis. Data from a Phase 2 clinical trial were recently presented on podium at the Osteoarthritis Research Society International (OARSI) World Congress 2024 in Vienna, Austria, where MOTYS™ was identified as a highly promising program to address the significant impact of debilitating osteoarthritis.
As part of the Series A financing, Doron is also adding two new board members: Karen Zaderej, and Tassos Konstantinou. Zaderej previously served as chief executive officer and as chairman of the board of directors of Axogen Inc. from 2010, led the company’s transformation from a start-up to a public company. Her experience advancing Avance Nerve Graft®, a biologically active human tissue graft, through BLA submission will be invaluable to Doron. Konstantinou, SPRIM’s managing director, is an investment professional with life science venture capital and business development experience that brings a broad and diversified global perspective.
FinSMEs
27/11/2024